Researchers show that anti-caries DNA vaccines, including pGJA-P/VAX, are good for preventing dental caries. In the report titled “Prospects in Caries Vaccine Development, it states that DNA vaccine approaches for dental caries have had a history of success in animal models. Dental caries vaccines, directed to key components of S. mutans colonization and enhanced by safe and effective adjuvants and optimal delivery vehicles, are likely to be forthcoming.

Related posts:

  1. Medicare Card, NIH begins testing investigational Zika vaccine in humans Medicare Card, NIH begins testing investigational Zika vaccine in humans...
  2. Medicare Card, Large-scale HIV vaccine trial to launch in South Africa Medicare Card, Large-scale HIV vaccine trial to launch in South Africa...
  3. Possible clues found to why HIV vaccine showed modest protection Insights into how the first vaccine ever reported to modestly prevent HIV infection in people might have worked were published online today in the New England Journal of Medicine. Scientists have found that among adults who received the experimental HIV vaccine during the landmark RV144 clinical trial, those who produced relatively high levels of a […]...
  4. Medicare Card, NIH-developed candidate dengue vaccine shows promise in early-stage trial Medicare Card, NIH-developed candidate dengue vaccine shows promise in early-stage trial...
  5. Medicare Card, Testing of investigational inactivated Zika vaccine in humans begins Medicare Card, Testing of investigational inactivated Zika vaccine in humans begins...
  6. Medicare Card, Testing of investigational inactivated Zika vaccine in humans begins Medicare Card, Testing of investigational inactivated Zika vaccine in humans begins...
  7. Medicare Card, Investigational malaria vaccine protects healthy U.S. adults for more than one year Medicare Card, Investigational malaria vaccine protects healthy U.S. adults for more than one year...
  8. Medicare Card, NIH launches early-stage yellow fever vaccine trial Yellow fever virus is found in tropical and subtropical, and caused an estimated 29,000 to 60,000 deaths in 2013. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has begun an early-stage clinical trial of an investigational vaccine designed to protect against yellow fever virus. The Phase 1 […]...
  9. Chikungunya vaccine trial begins to enroll participants An experimental vaccine to prevent chikungunya fever, a viral disease spread by certain species of mosquitoes, is being tested in a clinical trial conducted by National Institute of Allergy and Infectious Diseases (NIAID) scientists at the National Institutes of Health....
  10. Medicare Card, NIH-funded study to test pneumococcal vaccine in older adults Medicare Card, NIH-funded study to test pneumococcal vaccine in older adults...
  11. Medicare Card, NIH study finds factors that may influence influenza vaccine effectiveness Medicare Card, NIH study finds factors that may influence influenza vaccine effectiveness...
  12. Medicare, Funded HIV clinical research sites to join pediatric tuberculosis vaccine study Several U.S. government-funded HIV/AIDS clinical research sites in Africa will join other collaborators in an ongoing clinical trial testing an investigational tuberculosis (TB) vaccine in infants at risk for TB infection. “We are pleased to be able to tap into our existing HIV/AIDS clinical research infrastructure to help test promising investigational vaccines against TB,” said […]...
  13. Priming with DNA vaccine makes avian flu vaccine work better The immune response to an H5N1 avian influenza vaccine was greatly enhanced in healthy adults if they were first primed with a DNA vaccine expressing a gene for a key H5N1 protein, researchers say. Their report describes results from two clinical studies conducted by researchers from the National Institute of Allergy and Infectious Diseases (NIAID), […]...
  14. Medicare Card – NIH researchers make progress toward Epstein-Barr virus vaccine A research team led by scientists from NIH’s National Institute of Allergy and Infectious Diseases (NIAID) has determined how several antibodies induced by Epstein-Barr virus (EBV), a herpesvirus that causes infectious mononucleosis and is associated with certain cancers, block infection of cells grown in the laboratory. They then used this information to develop novel vaccine […]...
  15. Medicare Card: NIH-Supported Experimental Marburg Vaccine Prevents Disease Two Days after Infection An experimental vaccine developed to prevent outbreaks of Marburg hemorrhagic fever continues to show promise in monkeys as an emergency treatment for accidental exposures to the virus that causes the disease. There is no licensed treatment for Marburg infection, which has a high fatality rate....